We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure
Read MoreHide Full Article
Key Takeaways
Baxter lifts 2026 sales growth to 3%-4% and adjusted EPS guidance to $1.95-$2.15.
Q2 revenues rose 5% to $2.96B, with Advanced Surgery delivering 12% organic growth.
Baxter's margins fell as manufacturing costs, tariffs and higher-cost inventory pressured profits.
Baxter International Inc. (BAX - Free Report) raised its 2026 sales and adjusted earnings outlook after second-quarter results exceeded expectations. The update gives investors another data point on the company’s early-stage turnaround as operating execution improves.
The remaining question is whether better demand and cost actions can translate into sustained earnings improvement while margins face manufacturing, tariff and pricing pressure.
BAX Lifts 2026 Sales and Earnings Expectations
Baxter now expects 2026 reported sales growth of 3% to 4%, up from its prior forecast of flat to 1% growth. Organic sales are projected to increase 2% to 3%, compared with the earlier expectation of approximately flat growth.
Adjusted earnings guidance increased to $1.95-$2.15 per share from $1.85-$2.05. Management tied the stronger organic sales view to year-to-date performance and expected second-half growth, while the higher earnings outlook also incorporates the second-quarter tariff refund benefit.
Image Source: Zacks Investment Research
Baxter Q2 Results Show Broad-Based Organic Growth
Second-quarter revenues were $2.96 billion, up 5% on both a reported and organic basis. Adjusted earnings came in at 56 cents per share, ahead of expectations despite declining 5% from the year-ago period.
Medical Products & Therapies generated $2.08 billion in sales and grew 5% organically, while Healthcare Systems & Technologies posted $801 million and 4% organic growth. Advanced Surgery stood out with $331 million in revenues and 12% organic growth, supported by demand for hemostats and sealants.
BAX Margin Compression Tempers the Earnings Beat
The earnings beat did not remove profitability concerns. Adjusted gross margin fell 210 basis points to 38.6%, while adjusted operating margin declined 90 basis points to 14.2%.
Higher-cost inventory produced in late 2025, manufacturing costs and tariffs weighed on profitability. Medical Products & Therapies also saw a lower contribution from pricing. Baxter still expects full-year adjusted operating margin of 13% to 14%, leaving margin recovery dependent on stronger volumes, cost actions and improved inventory flow-through.
Baxter International Inc. Profit Margin (Quarterly)
The Novum IQ large-volume pump hold remains an execution risk. Lower Infusion Systems sales in the second quarter reflected the ongoing shipment and installation hold, customer returns and transitions to Spectrum, even as demand for Spectrum IQ remained steady.
Baxter has identified corrections and moved into early verification testing while continuing to work with regulators. The 2026 outlook still includes potential customer uncertainty around the hold, so a delayed normalization could continue to constrain Infusion Systems performance.
Becton, Dickinson and Company (BDX - Free Report) also competes in infusion technology through its Alaris system, underscoring the importance of reliable product availability in this market. ICU Medical, Inc. (ICUI - Free Report) sells IV smart pumps and other infusion-therapy products, giving hospital customers another established alternative within the broader infusion landscape.
BAX Ratings Keep the Outlook Balanced
Baxter’s raised guidance improves the earnings backdrop, but margin pressure and the unresolved Novum hold keep the turnaround from looking complete. The stock currently carries a Zacks Rank #3 (Hold), a rating consistent with a more balanced near-term setup rather than a clear directional signal. Both, Becton, Dickinson and Company and ICU Medical, also cayry a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BAX has a Value Score of B, Growth Score of B and VGM Score of B, providing favorable supporting characteristics across valuation and growth measures. Its Momentum Score of C is less supportive, reinforcing that stronger guidance by itself does not eliminate near-term execution uncertainty
View the Zacks #1 Rank List
Image: Bigstock
BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure
Key Takeaways
Baxter International Inc. (BAX - Free Report) raised its 2026 sales and adjusted earnings outlook after second-quarter results exceeded expectations. The update gives investors another data point on the company’s early-stage turnaround as operating execution improves.
The remaining question is whether better demand and cost actions can translate into sustained earnings improvement while margins face manufacturing, tariff and pricing pressure.
BAX Lifts 2026 Sales and Earnings Expectations
Baxter now expects 2026 reported sales growth of 3% to 4%, up from its prior forecast of flat to 1% growth. Organic sales are projected to increase 2% to 3%, compared with the earlier expectation of approximately flat growth.
Adjusted earnings guidance increased to $1.95-$2.15 per share from $1.85-$2.05. Management tied the stronger organic sales view to year-to-date performance and expected second-half growth, while the higher earnings outlook also incorporates the second-quarter tariff refund benefit.
Image Source: Zacks Investment Research
Baxter Q2 Results Show Broad-Based Organic Growth
Second-quarter revenues were $2.96 billion, up 5% on both a reported and organic basis. Adjusted earnings came in at 56 cents per share, ahead of expectations despite declining 5% from the year-ago period.
Medical Products & Therapies generated $2.08 billion in sales and grew 5% organically, while Healthcare Systems & Technologies posted $801 million and 4% organic growth. Advanced Surgery stood out with $331 million in revenues and 12% organic growth, supported by demand for hemostats and sealants.
BAX Margin Compression Tempers the Earnings Beat
The earnings beat did not remove profitability concerns. Adjusted gross margin fell 210 basis points to 38.6%, while adjusted operating margin declined 90 basis points to 14.2%.
Higher-cost inventory produced in late 2025, manufacturing costs and tariffs weighed on profitability. Medical Products & Therapies also saw a lower contribution from pricing. Baxter still expects full-year adjusted operating margin of 13% to 14%, leaving margin recovery dependent on stronger volumes, cost actions and improved inventory flow-through.
Baxter International Inc. Profit Margin (Quarterly)
Baxter International Inc. profit-margin-quarterly | Baxter International Inc. Quote
Baxter Novum Hold Remains a Key Guidance Risk
The Novum IQ large-volume pump hold remains an execution risk. Lower Infusion Systems sales in the second quarter reflected the ongoing shipment and installation hold, customer returns and transitions to Spectrum, even as demand for Spectrum IQ remained steady.
Baxter has identified corrections and moved into early verification testing while continuing to work with regulators. The 2026 outlook still includes potential customer uncertainty around the hold, so a delayed normalization could continue to constrain Infusion Systems performance.
Becton, Dickinson and Company (BDX - Free Report) also competes in infusion technology through its Alaris system, underscoring the importance of reliable product availability in this market. ICU Medical, Inc. (ICUI - Free Report) sells IV smart pumps and other infusion-therapy products, giving hospital customers another established alternative within the broader infusion landscape.
BAX Ratings Keep the Outlook Balanced
Baxter’s raised guidance improves the earnings backdrop, but margin pressure and the unresolved Novum hold keep the turnaround from looking complete. The stock currently carries a Zacks Rank #3 (Hold), a rating consistent with a more balanced near-term setup rather than a clear directional signal. Both, Becton, Dickinson and Company and ICU Medical, also cayry a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BAX has a Value Score of B, Growth Score of B and VGM Score of B, providing favorable supporting characteristics across valuation and growth measures. Its Momentum Score of C is less supportive, reinforcing that stronger guidance by itself does not eliminate near-term execution uncertainty